Bio-Techne Supplements Proxy With Goldman Valuation Details Amid Shareholder Lawsuit
TECH sits 67% above its 52-week low of $43.195.
Summary
Bio-Techne filed supplemental proxy disclosures detailing Goldman Sachs' valuation work and merger background after a shareholder lawsuit sought to block the September 23 vote on the $73 per share Merck KGaA acquisition.
Key Events · Legal and Risk Events · TECH
-
Shareholder Lawsuit Seeks to Enjoin Vote
Robert Garfield v. Baumgartner et al. was filed September 9, 2026 in Minnesota state court, alleging the proxy statement misrepresented or omitted material information and seeking to enjoin the September 23 shareholder vote on the Merck KGaA merger.
-
Supplemental Proxy Disclosures Filed
Bio-Techne voluntarily supplemented the proxy with details on prior acquisition interest from Party A and Party B, Goldman Sachs engagement terms, confidentiality agreements without standstills, and additional valuation inputs.
-
Goldman Valuation Inputs Disclosed
Goldman Sachs' analysis used total debt of ~$200M, cash of ~$210M, Wilson Wolf equity investment of ~$231M, Spear Bio investment of ~$15M, and 157.0M-157.8M fully diluted shares as of June 19, 2026, deriving illustrative present values of $45-$74 per share.
-
Prior Interest at Higher Prices Revealed
Parent verbally expressed interest in Q2 2023 at $92-$95 per share when Bio-Techne stock traded between $73.76 and $85.98 — above the current $73 deal price.
Analysis · TECH · Life Sciences
Facing a shareholder lawsuit seeking to enjoin the September 23 vote on the $73 per share Merck KGaA acquisition, Bio-Techne voluntarily supplemented its merger proxy with detailed Goldman Sachs valuation inputs and background disclosures. The new disclosures reveal that Parent verbally expressed interest at $92-$95 per share in Q2 2023 when the stock traded between $73.76 and $85.98 — a range above the current $73 deal price — and that Goldman's illustrative present values ranged from $45 to $74 per share. The company denies all allegations but made the supplements to avoid delaying the vote. The lawsuit and demand letters add uncertainty to the merger timeline, though Bio-Techne characterizes them as without merit.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.4% of the 1431 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TECH was trading at $72.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $43.20 to $72.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.